Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bone Biologics Corp. (BBLG : NSDQ)

• Company Description    Bone Biologics Corp. is a developer of orthobiologic products for spine fusion markets. Bone Biologics Corp. is based in BURLINGTON, Mass. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $2.13 Daily Weekly Monthly 20 Day Moving Average: 6,203,723 shares Shares Outstanding: 1.80 (millions) Market Capitalization: $3.82 (millions) Beta: 0.65 52 Week High: $16.50 52 Week Low: $1.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.36% -10.96% 12 Week -59.81% -63.49% Year To Date -62.24% -66.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 BURLINGTON WOODS DRIVE SUITE 100 - BURLINGTON,MA 01803 USA ph: 781-552-4452 fax: - jcain@allianceadvisors.com http://www.bonebiologics.com

• General Corporate Information    Officers Jeffrey Frelick - Chief Executive Officer and President Bruce Stroever - Chairman of the Board of Directors Deina H. Walsh - Chief Financial Officer Siddhesh Angle - Director Phil Meikle - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 098070600 SIC: 3842 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 1.80 Most Recent Split Date: 6.00 (0.17:1) Beta: 0.65 Market Capitalization: $3.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 66.91% vs. Previous Quarter: 30.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -100.58 03/31/25 - -130.21 12/31/24 - -118.67 ROA 06/30/25 - -93.31 03/31/25 - -119.39 12/31/24 - -109.95 Current Ratio 06/30/25 - 17.25 03/31/25 - 12.60 12/31/24 - 10.21 Quick Ratio 06/30/25 - 17.25 03/31/25 - 12.60 12/31/24 - 10.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 3.91 03/31/25 - 5.34 12/31/24 - 8.39 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©